Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT (Use as many sheets as necessary) of

Application Number	10/519,110	
Filing Date	July 2, 2003	
First Named Inventor	Etcheberrigaray	
Art Unit	Not Yet Assigned	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	17357 01001US	

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		US- 5,242,932	09/07/1993	Gandy et al.	
		us- 5,385,915	01/31/1995	Buxbaum et al.	
		US- 6,043,270	03/28/2000	Driedger et al.	
		US- 6,080,784	06/27/2000	Driedger et al.	
		^{US-} 6,407,058 B1	06/18/2002	Staddon et al.	
		US-			
-		US-			
		US-	0		
		US-			
		US-			

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ°
		JP 279311	03/26/1993			
		JP 240581	02/29/2000			
		JP 406279311A	10/04/1994	Tamura et al.		
		WO 2004/004641 A2	01/15/2004	Etcheberrigarary et al.		
		WO 97/43268	11/20/1997	Kozikowski		

	Examiner Signature	/Shengjun Wang/	Date Considered	07/02/2009
--	-----------------------	-----------------	--------------------	------------

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Oraw line through citation if not in conformance and not considered, include copy of his form with next communication to applicant. "Applicants unique citation designation number (options)." See Krints Codes of USPTO Partial December 3. See Vinits Codes of USPTO Partial December 3. See Vi Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, P.O. 80x 1456, Alexandris, VA.2. Statest TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
Substitute for form 14439/FTO	Application Number	10/519,110	
INFORMATION DISCLOSURE	Filing Date	July 2, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Etcheberrigaray	
	Art Unit	Not Yet Assigned	
(Use as many sheets as necessary)	Examiner Name	Not Yet Assigned	
Sheet 2 of	Attorney Docket Number	17357.01001US	

		•	
		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Indiude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title Initials* No. ¹ the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published.		Indude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Alkon, D.L. et al. "Regulation of Hermissenda K+ Channels by Cytoplasmic and Membrane-Associated C-Kinase," J. Neurochem., Vol. 51, No. 3, 1988	
		Bennett, Brian D., et al. "Expression Analysis of BACE2 in Brain and Peripheral Tissues." The Journal of Biological Chemistry, Vol. 275, No. 27, Issue of July 7, pp. 29647-20651, 2000	
		Bergamaschi, Stefania, et al. "Defective phorbol ester-stimulated secretion of B-amyloid precursor protein from Alzheimer's disease fibroblasts," Neuroscience Letters 201(1995) 1-4	
		Bondy, Brigitta, et al. "The PHA-Induced Calcium Signal in Lymphocytes is Altered After Blockade of K+-Channels in Alzheimer's Disease," J. Psychiat. Res. Vol. 30, No. 3, pp. 217-227, 1996	
		Burke, James R., et al. "Update on Alzheimer's Disease: Promising advances in detection and treatment," Postgraduate Medicine, Vol. 106, No. 5, October 15, 1999	
		Bury, Richard W. "PKC Activators (Phorbol Ester or Bryostatin) Stimulate Outgrowth of NFG-Depedent Neurites in a Subline of PC12 Cells," Journal of Neuroscience Research, 53:214-22 (199)	
		Buxbaum, Joseph D., et al. 'Evidence That Tumor Necrosis Factor a Converting Enzyme is involved in Regulated a-Secretase Cleavage of the Atbietimer Amyloid Protein Precursor,' The Journal of Biological Chemistry, Vol. 273, No. 43, Issue of October 23, pp. 27765-27767, 1998	
		Cai, Huaibin, et al. "BACE1 is the major B-secretase for generation of AB peptides by neurons," Nature Neuroscience, Vol. 4, No. 3, March 2001	
		Caputi, A., et al. "Increased Secretion of the Amino-Terminal Fragment of Amyloid Precursor Protein in Brains of Rats with a Constitutive Up-Regulation of Protein Kinase C," J. Neurochem., Vol. 88, No. 6, 1997	
		Cole, Gregory, et al. "Decreased levels of protein kinase C in Alzheimer brain," Brain Research, 452 (1988) 165-174	

	Signature	/Shengjun Wang/	Considered	07/02/2009
ľ	*EXAMINER: I	Initial if reference considered, whether or not citation is in conformance with MPE	609. Draw line through	citation if not in conformance and not

considered. Include copy of this form with next communication to applicant. considered, include copy or ties form with next communication or appearant, present a check mark here English language Translation is attached.

1 Applicant single calcitand esegration unmorter (goldrout) 2. Applicant is to present a check mark here English language Translation is attached.

1 In collection of the control of the contr

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Examiner

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO	40401171	X or 1000, no personic di	o roquitos so roquitos	Complete if Known
Substitu	te for form 1445/PTO			Application Number	10/519,110
INFO	ORMATION	DIS	CLOSURE	Filing Date	July 2, 2003
STATEMENT BY APPLICANT				First Named Inventor	Etcheberrigaray
	(Use es many she			Art Unit	Not Yet Assigned
	(Use es many sne	ets as n	ecessary)	Examiner Name	Not Yet Assigned
Sheet	3	of		Attorney Docket Number	17357.01001US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Connolly, Gerald P. "Fibroblast models of neurological disorders: fluorescence measurement studies," TIPS - May 1998 (Vol. 19)	
		Coughlan, Christine, et al. "Factors influencing the processing and function of the amyloid B pracursor protein - a potential therapeutic target in Aizheimer's disease?," Pharmacology & Therapeutics 86 (2000) 111-144	
		Desdouits, Frederic, et al. "Amyloid B Peptide Formation in Cell-free Preparations," The Journal of Biological Chemistry, Vol. 271, No. 40, Issue of October 4, pp. 24670-24674, 1996	
		Ethimiopoulos, Spiros, et al. "Intracellular Cyclic AMP Inhibits Constitutive and Phorbol Ester- Stimulated Secretory Cleavage of Amyloid Precursor Protein," J. Neurochem. Vol. 67, No. 2, 1996	
		Esler, William, et al. "A Portrait of Alzheimer Secretases - New Features and Familiar Faces," Science, Vol. 293, 24 August 2001	
		Etcheberrigaray, Rene, et al. "Calcium responses are altered in fibroblasts from Atzheimer's patients and pre- symptomatic PS1 cartiers: a potential tool for early diagnosis," Research Report, Alzheimer's Report, Vol. 3, Nos. 5 & 6, pp. 305-312 (2000)	
		Favit, Antonella et al. "Alzheimer's-specific effects of soluble B-amyloid on protein kinase C-a and -y degradation in human fibroblasts," Proc. Natl. Acad. Sci. USA Vol. 93, pp. 3562-5567, May 1998 Cell Biology	
		Gabuzda, Dana et al. "Inhibition of B-Amyloid Production by Activation of Protein Kinase C, "J. Neurochem. Vol. 61, No. 6, 1993	
		Gillespie, Susan L., et al. "Secretory Processing of the Alzheimer Amyloid B/A4 Protein Precursor is Increased by Protein Phosphorylation." Biochemical and Biophysical Research Communications, Vol. 187, No. 3, 1992	
		Ghosh, Arun, et al. "Design of Potent Inhibitors for Human Brain Memapsin 2 (B-Secretase)," J. Am. Chem. Soc. 2000, 122, 3522-3523	

	Signature	/Shengjun Wang/	Considered	07/02/2009
ı	*EXAMINER: I	nitiel if reference considered, whether or not citation is in conformance wi	th MPEP 609. Draw line through	citation if not in conformance and not

Examiner

considered. Include copy of this form with next communication to applicant.

considered. Include copy of his form with next communication to applicant.

1 Applicants runiper custom designation number (optional). Applicant is not be place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confiderability is governed by 3 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to that e2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, Any commentation amount of time by our require to complete this form and/or suggestions for reducing this burden, suppose that is sent to the Chef information code. My U.S. Peters and Trademan Orine, P.O. Box 1459, Alexandria, V.Z. 2213-1459.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/20/06. ONB 0955-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless its contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/519,110 INFORMATION DISCLOSURE Filing Date July 2, 2003 STATEMENT BY APPLICANT First Named Inventor Etcheberrigaray Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Attorney Docket Number 17357,01001US Sheet 4

of

Examiner

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Goekjian, Peter G., et al. "Protein Kinase C in the Treatment of Disease: Signal Transduction Pathways, Inhibitors, and Agents in Development." Current Chemistry, 1999, 6, 877-903	
		Govoni, S., et al. "Fibroblasts of patients affected by Down's syndrome oversecrete amyloid precursor protein and are hyporesponsive to protein kinase C stimulation," Neurology 1995; 48:1069-1075	
		Govoni, S., et al. "Cytosol protein kinase C downregulation in fibroblasts from Alzheimer's disease patients," Neurology 1993; 43:2581-2586	
		Haniu, Mitsuru, et al. "Characterization of Alzheimer's B-Secretase Protein BACE," The Journal of Biological Chemistry, Vol. 275, No. 28, Issue of July 14, pp. 21099-21106, 2000	
		Hardy, John "Amyloid, the presinilins and Alzheimer's disease," TINS, Vol. 20, No. 4, 1997	
		Hennings, Henry, et al. "Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin," Carcinogenesis, 8(9): 1343-1346 (1987)	
		Hofmann, Johann "The potential for isoenzyme-selective modulation of protein kinase C," The FASEB Journal, Vol. 11, July 1997	
		Hung, Albert Y, et al. "Activation of Protein Kinase C Inhibits Cellular Production of the Amyloid B- Protein." The Journal of Biological Chemistry, Vol. 268, No. 31, Issue of November 5, pp. 22959-22962, 1993	
		Huynh, Tuan Van, et al. "Reduced Protein Kinase C Immunoreactivity and Altered Protein Phosphorylation in Alzheimer's Disease Fibroblasts," Arch Neurol - Vol. 46, November 1999	
		lbarreta, Dolores, et al. "Benzolactam (BL) enhances sAPP secretion in fibroblasts and in PC12 cells," NeuroReport 10, 1035-1040 (1999)	

Signature	/Shengjun Wang/	Considered	07/02/2009
*EXAMINER:	nitial if reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through o	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant. considered, include copy or ins form with next communication to applicant.

1 Applicants unique cluston estignation number (optional). 2 Applicant is top space a check mark near 6 English lenguage Translation is statched.

This collection of information is required by 3 Creft 18. The set of the death or distance resident, benefit by the public sends in to file (and by the USPTO produced in the communication of the complete application from the the USPTO. Time will way depending upon the individual case. Any comments on the amount of time you require to complete shading on a communication of the communication of Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/519,110 INFORMATION DISCLOSURE Filing Date July 2, 2003 STATEMENT BY APPLICANT First Named Inventor Etcheberrigaray Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Attorney Docket Number Sheet 5 17357.01001US of

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*				
		Jin, Lee-Way, et al. "Changes in Protein Kinases in Brain Aging and Alzheimer's Disease," Drugs & Aging, 6(2) 1995	L	
		Jolly-Tornetta, Camille, et al. "Protein Kinase C Regulation of Intracellular and Cell Surface Amyloid Precursor Protein (APP) Cleavage in CHO695 Celts," Biochemistry 2000, 39, 15282-15290		
		Jolly-Tornetta, Camille, et al. "Regulation of Amyloid Precursor Protein (APP) by Protein Kinase Ca in Human Ntera 2 Neurons (NT2N)," Biochemistry 2000, 39, 7428-7435		
		Kinouchi, Tadatoshi et al. "Conventional protein kinase C (PKC)-a and novel PKCe, but not -s, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 371 fibroblasts," FEBS Letters 384 (1985) 203-206		
		Kozikowski, Alan P., et al. "Modeling, Chemistry, and Biology of the Benzolactam Analogues of Indolactam V (IUV). 2. Identification of the Binding Site of the Benzolaciams in the CRD2 Activator-Slnding Domain in PKCs and Discovery of an IUV Analogue of Improved Isozyme Selectivity." J. Med. Chem. 1997, 40, 1316-1328		
		Maiorini, A.F., et al. "Potential novel targets for Alzheimer pharmacotherapy: I. Secretase," Journal of Clinical Pharmacy and Therapeutics (2002) 27, 169-183		
		Masilah, E., et al. "Protein Kinase C Alteration Is An Early Biochemical Marker In Alzheimer's Disease," The Journal of Neuroscience, September 1991, 11(9): 2759-2676		
		Masilah, Eliezer "Role of Amytoid Precursor Protein in the Mechanisms of Neurodegeneration in Alzheimer's Disease," Laboratory Investigation, September 1997, Vol. 77, No. 3, p. 197		
		Hardy, J. "Molecular genetics of Alzheimer's disease," Acta Neurol Scand 1996: Supplement 165: 13-17		
		Mutter, Roger et al." Chemistry and Clinical Biology of the Bryostatins," Bioorganic & Medicinal Chemistry 8 (2000) 1841-1860		

Examiner Signature	/Shengjun Wang/	Date Considered	07/02/2009
AFWILLIAM FOLIA	til 14 fare and a second second second second platform is in conformance	with MDED 600. Draw line through ci	tation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

consumers, include Copy or this form with next commitment to application. If Applicants integric claims designated installant control in a property of the Copy of Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitute for form 1449/FTO	Application Number	10/519/110	
INFORMATION DISCLOSURE	Filing Date	July 2, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Etcheberrigaray	
(Use as many sheets as necessary)	Art Unit	Not Yet Assigned	
(Ose as many sneets as necessary)	Examiner Name	Not Yet Assigned	
Sheet 6 of	Attorney Docket Number	17357.01001US	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*				
		Nan, Fejun et al. "Dual Function Glutamate-Related Ligands: Discovery of a Novel, Potent Inhibitor of Glutamate Carboxypeptidase II Possessing mGtuR3 Agonist Activity," Journal of Medicinal Chemistry, 43 (5): 772-774		
		Neurology of Disease. Experimental Neurology, Part B, Vol. 5, No. 3, September 1998		
Ronner, S., et al. "Short Communication. Protein kinase Ca and B1 isoforms are regulators of a- secretory proteolytic processing of amyloid precursor protein in vivo," European Journal of Neuroscient Vol. 13, pp. 1644-1648, 2001.		secretory proteolytic processing of amyloid precursor protein in vivo," European Journal of Neuroscience,		
Savage, Mary J., et al. "Turnover of Amyloid B-Protein in Mouse Brain and Acute Reduction of I Level by Phorbol Ester," The Journal of Neuroscience, March 1, 1998, 18(5): 1743-1752				
		Scheuner, D., et al. "Secreted amyloid 8-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presentiin 1 and 2 and APP mutations linked to familial Alzheimer's disease." Nature Medicine, Vol. 2, No. 8, August 1996		
		Selkoe, Dennis J. "Alzheimer's Disease: Genes, Proteins, and Therapy," Pharmacoloical Review, Vol. 81, No. 2, April 2001		
		Selkoe, Dennis J. "Normal and Abnormal Biology of the B-Amyloid Precursor Protein," Annu. Re. Neurosci. 1994, 17:489-517		
		Selkoe, Dennis J. "Translating cell biology into therapeutic advances in Alzheimer's disease," Nature, Vol. 399, Supp. 34 June 1999		
		Shimohama, S., et al. "Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease," Neurology 1993: 43:1407-1413		
		Shoulson, Ira "Experimental Therapeutics of odenegerative Disorders: Unmet Needs," Science, Vol. 282, 6 November 1998		

Examiner Signature	/Shengjun Wang/	Date Considered	07/02/2009
*EVAMINED: I	sitial if reference considered, whether or not citation is in conformance with MPEP 60	Draw line through o	itation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Examiner

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

considered, include Cody of this form with next commitmentation to appreciate.

1. Applicant's running cultimon designation number (opdown). A perplacant is not pass a check mark here if English language Transition is attached.

1. Applicant's running cultimon designation number (opdown). A perplacant is not passed to achieve or reside a horself by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including a passed in the complete application from the full SYTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this busines, about be sent to the Chief Information Officer, U.S. Patent and Tandemark Office, P.O. Box 1450, Asendant's, N.A. 2231-3450, D.O.NOT SEND FEES OR COMPLETE PORRIST OT INS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

17357.01001US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449/PTO Application Number 10/519,110 INFORMATION DISCLOSURE Filing Date July 2, 2003 STATEMENT BY APPLICANT First Named Inventor Etcheberrigaray Art Unit Not Yet Assigned (Use as many sheets as necessary) Examiner Name Not Yet Assigned Attorney Docket Number

Sheet 7

of

considered. Include copy of this form with next communication to applicant.

Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate Initials* No.1 the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), voluments of the author (in CAPITAL LETTERS), title of the article (when appropriate the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), voluments of the author (in CAPITAL LETTERS).		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²
		number(s), publisher, city and/or country where published.	
		Sinha, Sukanto et al. "Purification and cloning of amyloid precursor protein B-secretase from human brain," Nature, Vol. 402, 2 December 1999	
		Skovronsky, Daniel M., et al. "Protein Kinase C-dependent a-Secretase Competes with B-Secretase for Cleavage of Amyloid: Precursor Protein in the Trans-Colgi Network." The Journal of Biological Chemistry, Vol. 275, No. 4, Issue of January 28, pp. 2586-2375, 2007.	
		Small, David H., et al. "Alzheimer's Disease and the Amyloid B Protein: What Is The Role of Amyloid?" Journal of Neurochemistry, Vol. 73, No. 2, 1999	
Szallasi, Zoltan et al. "Differential Regulation of Protein Kinase C Isozymes by Bryostatlin 1 and Phrobo 12-Myristate 13-Acetate in NIH 3T3 Fibroblasts," Jornal of Biochemistry, Vol. 269, No. 3, Issue of January 21, pp. 2118-2124, 1994			
		Tanzi, Rudolph E., et al. "The Gene Defects Responsible for Familial Alzheimer's Disease," Neurology of Disease 3, 159-168 (1996) Article No. 0016	
		Turner, Robert T., et al. "Specificity of Memapsin 1 and Its Implications on the Design of Memapsin 2 (B-Secretase) Inhibitor Selectivity," Biochemistry 2002, 41, 8742-8746	
		Varierasian, Mary L., et al. "Phase II Trial of Bryostatin 1 in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia," Clinical Cancer Research, Vol. 6, 825-828, March 2000	
		Vassar, Robert et al. "AB-Generating Enzymes: Recent Advances in B- and y-Secretase Research, Neuron, Vol. 27, 419-422, September 2000	
		Vassar, Robert et al. "B-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," Science, Vol. 286, 22 October 1999	
		Wang, Hoau et al. "Attenuated Protein Kinase C Activity and Translocation in Alzheimer's Disease Brain," Neurobiology of Aging, Vol. 15, No. 3, pp. 293-298, 1994	

Examiner Signature	/Shengjun Wang/	Date Considered	07/02/2009	
*EXAMPLES: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not				

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentifiatily is powered by \$5 U.S. C. 12 and \$7 CFR 1.14. This collection is estimated to lake 2 hours to complete, including to process) an application. Confidentifiatily is powered by \$5 U.S. C. 12 and \$7 CFR 1.14. This collection is estimated to lake 2 hours to complete, including the confidence of the confid agenting, preparing, and submitting to complete depictation from the ILVTO. Time will vary depending upon the inclination of the Complete application from the ILVTO. Time will vary depending upon the inclination case. Any comments on the amount of time you require to complete his form and/or suggested for reducing the bases, should be sent to the Chief Individual case. Any comments on the amount of time you require to complete his family and and suggested for reducing the bases, should be sent to the Chief Individual case. Any comments on the amount of time you require to Chief Individual case. Any comments on the amount of time you require to the Chief Individual case. Any comments on the amount of time you require to the Chief Individual case. Any comments on the amount of time you require to the Chief Individual case. Any comments on the chief Individual case. Any comme Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/3 1/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known		
Substitute for form 14457-10	Application Number	10/519,110		
INFORMATION DISCLOSUR	Filing Date	July 2, 2003		
STATEMENT BY APPLICAN	First Named Inventor	Etcheberrigaray		
	Art Unit	Not Yet Assigned		
(Usa as many sheets as necessary)	Examiner Name	Not Yet Assigned		
Sheet 8 of	Attorney Docket Number	17357.01001US		

C	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Webb, Benjamin L.J., et al. "Protein kinase C isoenzymes: a review of their structure, regulation and role in regulating airways smooth muscle tone and mitogenesis." British Journal of Pharmacology (2000) 130, 1433-1452	
		Wiltfang, Jens et al. "Molecular Biology of Alzheimer's Dementia and Its Clinical Relevance to Early Diagnosis and New Therapeutic Strategies," Gerontology 2001; 47:65-71	
		Xu, Huaxi et al. "Metabolish of Alzheimer B-Amyloid precursor protein: Regulation by protein kinase A In intact cells and in a cell-free system," Proc. Natl. Acad. Sci. USA, Vol. 93, pp. 4081-4084, April 1996	
		Zhang, Xueshu et al. "Preclinical Pharmacology of the Nature Product Anticancer Agent Bryostatin 1, an Activator of Protein Kinase C1," Cancer Research 56, 802-808, February 1996	

ľ	*FYAMINER: I	nitial if reference considered, whether or not citation is in conformance with	MDED 600 Draw line through of	tation if not in conformance and not
	Signature	/Shengiun Wang/	Considered	07/02/2009
	Examine		Date	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

considered, induced copy or test form with field communication to applicate.

Applicants in using calcidation designation manufact (goldonii). Applicant is using calcidation designation cannot (goldonii). Applicant is not required to obtain or retain a barnetit by the public which is to the (and by the USFTO to process) an application. Confideritality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including a public which is to the complete, including a public which is to complete, including a public which is to complete that a complete depiction from the five STOT. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this complete that complete the publication from the five STOT. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this complete that the complete public which is the complete that the complete public which is to the complete public which is to the complete public which is the complete public which is to the complete public which